In order to explore the neuroprotective and crossspecies activities of C-peptide on type 1 diabetic neuropathy, spontaneously diabetic BB/W-rats were given increasing doses of human recombinant Cpeptide (hrC-peptide). Diabetic rats received 10, 100, 500, or 1000g of hrC-peptide/kg body weight/ day from onset of diabetes. After 2 months of hrCpeptide administration, 100g and greater doses completely prevented the nerve conduction defect, which was associated with a significant but incomplete prevention of neural Na+/K+-ATPase activity in diabetic rats with 500 g or greater C-peptide replacement. Increasing doses of hrC-peptide showed increasing prevention of early structural abnormalities such as paranodal swelling and axonal degeneration and an increasing frequency of regenerating sural nerve fibers. We conclude that hrC-peptide exerts a dose dependent protection on type 1 diabetic neuropathy in rats and that this effect is probably mediated by the partially conserved sequence of the active C-terminal pentapeptide.
INTRODUCTION
There is now mounting evidence demonstrating that C-peptide has preventive and ameliorating effects on the chronic complications of type 1 diabetes in both humans and experimental animal models [1] [2] [3] .
In a recent study [4] , we demonstrated the preventive and therapeutic effects of rat II C-peptide on the acute and chronic metabolic, functional and structural abnormalities of diabetic polyneuropathy (DPN) in type 1 diabetic BB/Wor-rat. Although, it is not clear how C-peptide exerts these beneficial effects, recent studies suggest that C-peptide has insulinomimetic metabolic and mitogenic effects [5] [6] [7] . A specific C-peptide receptor has not yet been characterized [8] . The metabolic effects of C-peptide include corrective effects on nerve Na+/K+-ATPase and endothelial NO [7] [8] [9] [10] , which has been associated with its beneficial effects on peripheral nerve function in experimental type 1 diabetic rat models and humans [1, 4, 10] . C-peptide has by itself no effect on hyperglycemia [4, 11] .
It has been proposed that the mid-portion of human C-peptide mediates all or part of its biological activity [1] , since it is highly conserved in mammalian species. On the other hand, the C-terminal pentapeptide, which possesses receptor/ ligand type interaction shows the same biological activity as the entire 31 amino acid C-peptide [8, 11] . In the present study we examined the dose response relationship between four doses of human recombinant C-peptide (hrC-peptide) given (Fig 1) . Non-hrC-peptide replaced diabetic animals showed a 58% (p < 0.01) reduction in Na+/K+-ATPase activity compared to control rats (Fig 2) . Ten and 100 pg hrC-peptide showed no significant prevention of the Na+/ K+-ATPase defect, whereas 500 and 1000g completely (p < 0.05) prevented the deficit in Na + / K+-ATPase activity.
Teased Sural Nerve Fibers Two months of diabetes revealed structural abnormalities of 20% (p<0.001) of sural nerve myelinated fibers. Ten g of hrC-peptide had no effect on the frequency of normalcy, whereas 100, 500 and 1000 g showed significant prevention (p < 0.01 for 100 txg; p < 0.001 for 500 and 1000 g) of myelinated fiber pathology, although it was not completely prevented when compared to control rats (Fig 3) . The most profound structural change at this stage of type 1 diabetes is the Na+/K+-ATPase related paranodal swelling [4, 14] . This was increased almost 5-fold (p < 0.001) in non-hrC-peptide replaceded diabetic rats, but was prevented by 52 and 70% in 500 and 1000 g hrC-peptide replaced animals respectively (both p < 0.001; Fig 4) , although these values were not normal (p<0.001) (Fig 4) . Paranodal swelling is followed by paranodal demyelination [4, 12] , which was exhibited by 1.8% of fibers in non-hrC-peptide replaced diabetic rats (Fig 5) .
Ten and 1001g of hrC-peptide had no effect on paranodal demyelination, whereas 500 and 1000txg fully (p<0.001) prevented paranodal demyelination (Fig 5) . Axonal degeneration, comprised of excessive myelin wrinkling, reflecting axonal atrophy, and Wallerian degeneration, was increased 3-fold (p < 0.001) in non-treated diabetic rats (Fig 6) (p <0.001) prevented by 1000 txg of hrC-peptide (Fig 6) .
Increasing doses of hrC-peptide promoted nerve fiber regeneration in the sural nerve, the frequencies of which were significantly (p < 0.001) increased in 500 and 1000g replaced animals (Fig 7) . [12] , that DPN in type 1 rats is caused by a hyperglycemic component and a C-peptide responsive component. Since activation of the polyol pathway is also associated with these early structural changes [15] and is not corrected by C-peptide replacement [4] , it is possible that the residual structural abnormalities in the present study reflect polyolpathway induced abnormalities similar to those seen in the milder DPN of type 2 BB/Z-rats [12] . The prevention of the Na+/K+-ATPase defect in diabetic peripheral nerve is in keeping with our previous data [4] and those of others [1, 9] , and probably accounts for the prevention of the early metabolic NCV defect, which is closely associated with decreased Na+/K+-ATPase activity [16] . Nodal [19] have demonstrated that the insulin receptor co-localizes with paranodal axoglial junctions in peripheral nerve. We [19] and others [20] have suggested that insulin may have a regulatory effect on nodal tight junction integrity. This is consistent with C-peptide's insulinomimetic and preventive effects on disruption of paranodal axo-glial junctions and paranodal demyelination. The dose related increase in nerve fibe,r regeneration is in agreement with our previous study [4] and is possibly related to Cpeptide's corrective effect on IGF-1 expression in peripheral nerve [21] . Although not examined in the present study, C-peptide has an ameliorating effect on endothelial NO [22] . Such a beneficial effect on NO and microcirculation is likely to improve endoneurial blood flow, hence contributing to the prevention of DPN.
The amino-acid sequence of C-peptide shows considerable species variations [8] . It has been suggested that the conserved midportion mediates its biological effect [1] . However, this has not been confirmed by others [8, 11] , who instead have shown that the C-terminal pentapeptide is responsible for C-peptide activity. The active Cterminal pentapeptide differs by three aminoacids between rat and man. In the present study approximately 104 higher concentrations of hrCpeptide was necessary to achieve the same effects as those reported with rat II C-peptide (75nmol/kg body weight/day) [4] , which may be due to the only partially conserved regions of the C-terminal which possesses the receptor/ ligand type interaction [8] .
In summary the present study has shown dose-dependent effects of hrC-peptide on early DPN in the type 1 diabetic BB/Wor-rat, demonstrating its preventative effect and cross-species activity which is likely mediated by the partially conserved sequence of the biologically active C-terminal.
